Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.

Slides:

Advertisements

Similar presentations

HFCWO and CF Is it Worth it?. Uses To loosen thick secretions that would otherwise remain in the lung Primarily indicated for Cystic Fibrosis patients.

Advertisements

Pneumonia: nursing management Islamic University Nursing College.

The Cystic Fibrosis Therapeutics Development Network and CF Clinical Research at UNM Jennifer L. Taylor-Cousar, MD Assistant Professor, Adult CF Program/Associate.

 The first known definition of Cystic Fibrosis was written in 1938 by Dr. Dorothy Anderson, a pathologist in the New York Babies Hospital.  In the 17.

BY ELIZABETH LITTLE AND LEAH RAYGO Cystic Fibrosis: The Crisis in Ireland.

Cystic Fibrosis Autosomal recessive Faulty gene causes mucus to build up in lungs, –Become infected Lung damage usually causes early death Treatments:

Cystic Fibrosis Lela Biggus pd. 8.

New Developments in Cystic Fibrosis

By: Paige Whalen and Alex Ung.  Mutation in the gene called cystic fibrosis transmembrane conductance regulator.  Due to loss of chromosome, located.

Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.

Brief History in USA & UK

Research collaboration in CF

Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection

Specialised Services: harm and mortality reduction

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Pseudomonas Infection in Cystic Fibrosis

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Starting Strong: Initial Evaluation of the Patient With HCV

Pseudomonas Lung Infections in Cystic Fibrosis

Brown SMN1,2, Bush A1,2, Davies JC1,2, Thursfield R1,2, Lloyd CM1

This Program Will Discuss

Advances in Cystic Fibrosis 2017

Patient-Centered Care in Cystic Fibrosis

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Gut bacterial microbiota and obesity

Entry Task: Educated Guess!

Infections in Patients with Cystic Fibrosis

Assessing Disease Progression in MS Treatment

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Evaluating Effects of CFTR Modulation in Cystic Fibrosis

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Advances in Cystic Fibrosis: Perspectives from Phoenix 2015

Shoshi Armoni RN, BSN Cystic Fibrosis Center

Primary Biliary Cholangitis

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Cystic Fibrosis Autosomal recessive Faulty gene causes mucus to build up in lungs, Become infected Lung damage usually causes early death Treatments:

New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Frank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne J

The National Biome Initiative: An allergy perspective

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A. Oliver, A. Mena Clinical Microbiology and Infection

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Addressing Treatment Challenges in Cystic Fibrosis

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

UK Cystic Fibrosis Registry Annual Data Report 2017

A.H. Gifford Journal of Cystic Fibrosis

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

The Patient With Early Stage MF-CTCL

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

November, 2018 Ljubljana, Slovenia

Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function Kavitha Kotha, Rhonda D. Szczesniak,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Strategies for Infection Control in Cystic Fibrosis

Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.

CFTR modulators and pregnancy: Our work has only just begun

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Kian Fan Chung, MD, DSc, FRCP

Daniel V Schidlow, M.D. Journal of Cystic Fibrosis

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

The Stillwater Times Dr. Patrauchan’s work with Cystic Fibrosis

Presentation transcript:

Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016

Infection and Microbiota of the Lung and Gut

Predictors of IV Antibiotic Treatment Failure

Findings

Trends in Pseudomonas Infection, UK Registry Data

Unexpected Findings

Effect of Changes in Gut Microbiota in CF

CFTR Modulator Ivacaftor Experience

Analysis of Disease Progression With Ivacaftor

Findings

Question?

Effect of CFTR Modulator Therapy on Airway Bacterial Composition

Findings

Inflammation and the Microbiome

Effects of Lumacaftor/Ivacaftor on Biomarkers of Systemic Inflammation

CF-SpIT Study Lower Airway Microbiome in Young Children

Predictive Markers of PA Infection

Perspective

Patient Education and Self-Management Tools

What Do Patients Want From an Electronic Clinical Record?

Patient Preferences in ECR

Patient Perspectives on Access to Registry Data

Access to Registry Data

Patient Education Linked to Quality Improvement Program

Findings

Abbreviations

Abbreviations